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Sukit Yamwong1, Unchalee Permsuwan2*, Sirana Tinmanee3 and Piyamitr Sritara1Abstract
Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded
clopidogrel and ASA in patients with ACS based on a Thai cost database.
Methods: A one-year decision tree and a long-term Markov model were constructed to estimate lifetime costs and
quality-adjusted life years (QALYs). For the first year, data from PLATO (NCT00391872) were used to estimate the
rate of cardiovascular events, resource use, and QALYs. For year 2 onwards, clinical effectiveness was estimated
conditional on individual health states that occurred during the first year.
Results: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) with ticagrelor was 292,504 ($9,476)
and 60,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability
of ticagrelor being cost-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded
clopidogrel.
Conclusions: This health economic analysis provides cost effectiveness data for ticagrelor compared with both
generic and branded clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically
valuable treatment for ACS compared with branded clopidogrel within the Thai context.
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Acute coronary syndrome (ACS) is a common cardio-
vascular disease associated with high complication and
mortality rates. From the Thai ACS Registry – a survey
conducted at 17 tertiary care centers in 2007 – the in-
hospital mortality rate was 12.6% [1]. A later survey in
2012 showed a lower rate of in-hospital mortality (4.8%)
but the mortality rate at one-year had not decreased
(17.7%) [2]. Moreover, a study of ACS patients under the
Universal Coverage (UC) scheme and Civil Servant Med-
ical Benefits Scheme (CSMBS) at all levels of hospital
found that the in-hospital mortality rate was approximately
14%, and that ACS was associated with substantial health
care use and costs [3,4]. Various anti-platelet drugs have
been proven to reduce cardiovascular events in ACS pa-
tients. Currently, there are several classes of anti-platelet* Correspondence: unchalee.permsuwan@gmail.com
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in any medium, provided the original work is pdrugs available on the market including aspirin (ASA),
thienopyridine products such as clopidogrel or prasugrel,
and a new chemical class, the cyclopentyltriazolopyrimi-
dines, which includes the direct-acting oral antagonist of
the adenosine diphosphate P2Y12 receptor ticagrelor.
According to the 2012 American College of Cardiology/
American Heart Association guidelines, combined treat-
ment with ASA plus a P2Y12 inhibitor such as clopidogrel,
prasugrel or ticagrelor is recommended as standard anti-
platelet treatment in ACS [5]. However, clopidogrel is a
pro-drug requiring transformation to an active metabolite,
which results in a slower onset and less consistent inhib-
ition of platelet aggregation compared with ticagrelor [6].
Ticagrelor represents a new treatment option for ACS.
The PLATelet inhibition and patient Outcomes (PLATO)
study was conducted to determine whether ticagrelor is
superior to clopidogrel for the prevention of vascular
events and death in a broad population of patients pre-
senting with an ACS [7]. Thailand was a part of thisis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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pidogrel in combination with ASA, ticagrelor in combin-
ation with ASA demonstrated superior efficacy in the
prevention of thrombotic events for the composite end-
point of vascular death, myocardial infarction (MI), or
stroke (9.8% vs 11.7%, hazard ratio [HR] = 0.84; 95% CI
0.77 to 0.92; p < 0.001). Trial-defined major bleeding
events were similar in both treatment groups, but there
were statistically significantly more combined major and
minor bleeding events in the ticagrelor arm compared
with the clopidogrel arm (16.1% vs 14.6%, HR = 1.11;
95% CI 1.03 to 1.30; p = 0.008) and more non-coronary
artery bypass grafting (non-CABG) related major blee-
ding events (4.5% vs 3.8%, HR = 1.19; 95% CI 1.02 to
1.38; p = 0.03).
Treatment of ACS imposes a substantial burden on Thai
society as a whole. When a new treatment becomes avail-
able, especially one with a higher cost but greater benefit
than usual care, it is necessary to critically appraise the
cost-effectiveness of this new treatment to determine
whether the improvement in treatment efficacy makes fi-
nancial sense, especially in the era of limited healthcare re-
sources. Therefore, this study aimed to evaluate the long-
term cost-effectiveness of ticagrelor and ASA versus clopi-
dogrel and ASA in ACS patients in Thailand.
Methods
A two-part construct model with a one-year decision





One-year decision tree 





Start state in 
long-term
Markov model
Figure 1 One-year decision tree model and long-term Markov modelwas used to compare ticagrelor with generic and branded
clopidogrel. The model was designed to capture short-
and long-term costs and outcomes. The clinical effective-
ness data were obtained from the PLATO trial [7] while
cost data were derived from a Thai database. All costs and
effects were discounted at 3% per annum as indicated by
Thai guidelines [9]. Costs were presented in the year 2013
and effectiveness was measured in terms of quality
adjusted-life years (QALYs). The health care payer per-
spective was undertaken.
The decision model
To model the short-term cost-effectiveness of ticagrelor,
a one-year decision tree covering four mutually exclusive
health states (no further event, non-fatal MI, non-fatal
stroke, and death from any cause) was constructed as
shown in Figure 1. During this phase, each ACS patient
received clopidogrel 75 mg once daily plus ASA 75–
100 mg or ticagrelor 90 mg twice daily plus ASA 75–
100 mg for 12 months. We assumed the treatment
duration lasted only one year and that there was no
rebound effect for treatment remaining in the Markov
cycles. At the end of one year, patients were allocated to
one of the six mutually exclusive health states in the
Markov model: no further event, non-fatal MI, post MI,
non-fatal stroke, post stroke and dead (Figure 1). The
non-fatal MI and non-fatal stroke health states were
tunnel states allowing for a worse prognosis for pa-













Long-term Markov extrapolation model
1. Risk of non-fatal MI for patients with no further event in the PLATO study
2. Risk of non-fatal stroke for patients with no further event in the PLATO study
3. Mortality risk for patients with no further event from Thai Life table  
4. Mortality risk first year after a non-fatal MI 
5. Mortality risk first year after a non-fatal stroke
6. Mortality risk second and subsequent year after a non-fatal MI
7. Mortality risk second and subsequent year after a non-fatal stroke
4 5
(adapted from PLATO) [7].
Table 2 Input parameters and values used in the
economic model
Input parameters Value Source
One-year decision tree
Ticagrelor
No event 0.894 PLATO [7], Nikolic [8]
Non-fatal MI 0.050 PLATO [7], Nikolic [8]
Non-fatal stroke 0.010 PLATO [7], Nikolic [8]
Death any cause 0.046 PLATO [7], Nikolic [8]
Clopidogrel
No event 0.875 PLATO [7], Nikolic [8]
Non-fatal MI 0.057 PLATO [7], Nikolic [8]
Non-fatal stroke 0.009 PLATO [7], Nikolic [8]
Death any cause 0.059 PLATO [7], Nikolic [8]
Markov modela
Annual risk of MI in the no
event state
0.019 PLATO [7], Nikolic [8]
Annual risk of stroke in the
no event state
0.003 PLATO [7], Nikolic [8]
Risk of death in no event stateb 2.000 Thai Life table [10],
Allen [11], Taneja [12]
Risk of death in the non-fatal
MI stateb
6.000 PLATO [7], Nikolic [8]
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post-stroke states would remain in those states for all suc-
ceeding cycles until they moved to death state. The cycle
length was one year with a lifetime horizon. We assumed
our Thai cohort of ACS patients had a median age of
62 years (based on PLATO data [7] and consistent with
the average age of ACS patients in the Thai Registry report
[2]) and had similar percentages of ST segment elevation
myocardial infarction (STEMI), non-ST segment elevation
myocardial infarction (NSTEMI), and unstable angina
(UA) as patients enrolled in the PLATO trial (Table 1) [7].
Effectiveness parameters
For a one-year decision tree, the effectiveness data were
derived exclusively from the PLATO trial [7], as Thailand
was included in this multi-centre study. A parametric
time-to-event survival model with a Weibull distribution
was employed in order to determine the baseline risk of
events with clopidogrel treatment and a hazard ratio (HR)
of ticagrelor treatment effect. Hence, the ticagrelor event
rates were the product of baseline risk and a ticagrelor HR
(Table 2).
Due to patients no longer being on study medications
after one year according to our assumption, the identical
transition probabilities for the second year onwards wereTable 1 Baseline characteristics of patients in the PLATO





Age — median (range) 62.0 (19–97) 62.0 (21–94)
Female sex — no. (%) 2655 (28.4) 2633 (28.3)
BMI — median (range) 27 (13–68) 27 (13–70)
Cardiovascular risk factor —
no./total no. (%)
Habitual smoker 3360 (36.0) 3318 (35.7)
Hypertension 6139 (65.8) 6044 (65.1)
Dyslipidemia 4347 (46.6) 4342 (46.7)
Diabetes mellitus 2326 (24.9) 2336 (25.1)
Other medical history —
no./total no. (%)
MI 1900 (20.4) 1924 (20.7)
Percutaneous coronary
intervention
1272 (13.6) 1220 (13.1)
Congestive heart failure 513 (5.5) 537 (5.8)
Final diagnosis of ACS —
no./total no. (%)
ST-elevation MI 3496 (37.5) 3530 (38.0)
Non–ST-elevation MI 4005 (42.9) 3950 (42.5)
Unstable angina 1549 (16.6) 1563 (16.8)
Other diagnosis or missing
data
283 (3.0) 248 (2.7)
*Adapted from PLATO [7].
Risk of death in the post MI stateb 3.000 PLATO [7], Nikolic [8]
Risk of death in the non-fatal
stroke stateb
7.430 Dennis [13], Hanke [14]
Risk of death in the post stroke
stateb
3.000 PLATO [7], Nikolic [8]
aThe values in the Markov model are the same for ticagelor and clopidgrel.
bHazard ratio over standard mortality.employed in both treatment strategies in the Markov
model. The difference in both groups occurred for the
proportion of patients in the different start states in
the Markov model. The transition probabilities from no
event to non-fatal MI or non-fatal stroke in the Markov
model were estimated with an extrapolation of the ob-
served HRs in the clopidogrel arm of PLATO beyond
1 year [7,8]. The annual mortality rate (MR) in the no-
event state was estimated using age- and gender-specific
MR from Thai lifetables [10]. To incorporate an in-
creased risk of mortality associated with ACS, a HR was
applied to the age- and gender-specific MR of the Thai
population. Patients suffering an ACS event have a rela-
tively high risk of a fatal event occurring within one year
and the risk declines over time the longer that patients
survive without a subsequent ACS event [11,12]; hence,
the risk of death for patients in the no-event state was
double that of standard mortality risk from Thai lifeta-
bles. The mortality risks of non-fatal MI, post-MI, and
post-stroke were estimated by extrapolation of PLATO
trial data [7]. The mortality risks of non-fatal stroke
were derived from the literature [13,14].






Annual drug cost 34,368 Manufacturer’s price
No event 117,404 Nikolic [8], Riewpaiboon [16]
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Utilities within the one-year decision tree were based on
EQ-5D data collected within the PLATO study [7,8]. In
the Markov model, the baseline utility of the no-event
state was also derived from the PLATO trial [7,8]. A
decrement due to each health state was applied based on
a previous study conducted in Thailand [15] (Table 3).
Resource and cost parameters
This study was carried out from the viewpoint of the
payer; hence, only direct medical costs were taken into
consideration. These included study medication, con-
comitant medications, hospitalizations, investigations,
interventions, and bleeding-related resources. For the
one-year decision tree, healthcare costs incurred in each
treatment arm were based on resource used data from
the PLATO trial [7,8] and unit costs of those resources
from data in Thailand (Additional file 1: TableS1) [16,17].
The cost of ticagrelor used was based on the manufac-
turer’s price (94.16 THB per day). Clopidogrel costs were
derived from the Drug and Medical Supply Information
Center (DMSIC) in Thailand (branded = 72.53 THB per
day and the cheapest generic = 0.94 THB per day) [18].
The drug costs included 7% VAT. For year 2 onwards, the
individual total cost of each health state was exclusively




No event 0.873 PLATO [7], Nikolic [8]
Non-fatal MI 0.811 PLATO [7], Nikolic [8]
Non-fatal stroke 0.735 PLATO [7], Nikolic [8]
Death any cause 0.247 PLATO [7], Nikolic [8]
Clopidogrel
No event 0.876 PLATO [7], Nikolic [8]
Non-fatal MI 0.814 PLATO [7], Nikolic [8]
Non-fatal stroke 0.738 PLATO [7], Nikolic [8]
Death any cause 0.250 PLATO [7], Nikolic [8]
Markov modela
No event aged less than
70 years
0.875 PLATO [7], Nikolic [8]
No event aged 70–79 years 0.843 PLATO [7], Nikolic [8]
No event aged over 79 years 0.781 PLATO [7], Nikolic [8]
Annual utility decrement MI
1st year Markov model and
2nd year onward
0.147 Tamteeranon [15]
Annual utility decrement stroke
1st year Markov model and
2nd year onward
0.226 Tamteeranon [15]
aThe values in the Markov model are the same for ticagelor and clopidogrel.adjusted to the year 2013 using the consumer price index
(medical care component) [19]. Table 4 presents the total
costs used in this study.
Model analyses
Costs and QALY were calculated over a lifetime horizon
and presented as the incremental cost-effectiveness ratio
(ICER) which was the ratio of an incremental cost and
an incremental QALY. The model was constructed and
run using Microsoft Excel version 2007.
Sensitivity analyses
A series of sensitivity analyses were carried out to ad-
dress uncertainty of parameters in the model. One-way
sensitivity analysis was conducted to assess the uncer-
tainty surrounding each parameter individually. The var-
iables tested in the one-way sensitivity analysis included
all transition probabilities, utilities and cost parameters.Non-fatal MI 204,851 Nikolic [8], Riewpaiboon [16],
Central office for Healthcare
Information [17]
Non-fatal stroke 141,918 Nikolic [8], Riewpaiboon [16]








No event 120,307 Nikolic [8], Riewpaiboon [16]
Non-fatal MI 207,753 Nikolic [8], Riewpaiboon [16],
Central office for Healthcare
Information [17]
Non-fatal stroke 144,821 Nikolic [8], Riewpaiboon [16]
Death any cause 123,034 Nikolic [8], Riewpaiboon [16]
Markov model
Total cost MI 1st year
Markov model
168,196 Anukoolsawat [4]
Total cost MI 2nd year
and onward
35,926 Anukoolsawat [4]
Total cost stroke 1st year
Markov model
79,800 Tamteeranon [15]
Total cost stroke 2nd year
and onward
12,642 Tamteeranon [15]
Total cost of no event 21,866 Anukoolsawat [4]
aDetailed table of Thai hospital charges and unit cost (Baht) for the resource
use collected in the PLATO trial provided in the Additional file 1: Table S1.
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then by a reduction of 50% and an increase of 200%. All
cost parameters were varied by 20% except drug costs,
the ticagrelor cost was varied by 10% while the cost of
the least expensive generic clopidogrel was set at 10%
lower than current prices, and the cost of branded clopi-
dogrel was set at 10% higher than current price. The re-
sults were presented as a tornado diagram. Probabilistic
sensitivity analysis (PSA) was also undertaken. With the
assigned distribution to each model parameter, uncer-
tainty was then propagated through the model using
Monte Carlo Simulation with parameter values drawn at
random. The decision analysis model was simulated on a
thousand iterations. The PSA results of ticagrelor vs
branded clopidogrel and ticagrelor vs generic clopidogrel
were presented as cost-effectiveness acceptability curves.
For the Thai context, an ICER of less than 160,000 THB/
QALY is considered cost effective [20]. This is consistent
with WHO recommendations that an ICER of 1GDP per
capita demonstrates acceptable cost-effectiveness, while
an ICER of over 3GDP per capita is justified to be
considered not cost-effective [21]. The GDP per capita in
Thailand in 2013 was 174,658 THB [22,23].
Results
The results showed that, compared with either generic
or branded clopidogrel, ticagrelor treatment had a higher
total cost with higher QALY. However, the difference in
cost was less marked in analyses using branded versus
generic clopidogrel (6,553 vs 31,918 THB respectively)
resulting in a lower ICER of branded clopidogrel than
generic clopidogrel (60,055 vs 292,504 THB/QALY re-
spectively) compared with ticagrelor (Table 5).
Sensitivity analysis
Of the 26 variables tested in one-way sensitivity analyses,
we found that the cost of clopidogrel, the cost of the
no-event state within the trial of both ticagrelor and
clopidogrel, and the HR of standard mortality in the no-
event state had the greatest impact on ICER (Figure 2).Table 5 Base-case result
Ticagrelor Clopidogrel Incremental ICER
Ticagrelor vs generic clopidogrel
Costs (THB) 368,747 336,829 31,918
Life-years 9.201 9.079 0.122 261,197
QALYs 7.711 7.602 0.109 292,504
Ticagrelor vs branded clopidogrel
Costs (THB) 368,747 362,194 6,553
Life-years 9.201 9.079 0.122 53,627
QALYs 7.711 7.602 0.109 60,055
QALYs: Quality adjusted-life years; ICER: Incremental cost-effectiveness ratio.Compared with branded clopidogrel, ticagrelor had more
than 99% probability of being cost-effective within the
predefined threshold of 160,000 THB/QALY. However,
ticagrelor was less cost-effective compared with generic
clopidogrel (Figure 3).
Discussion
We conducted a cost-effectiveness study using an ana-
lytical model to examine whether the new treatment,
ticagrelor in combination with ASA, was cost-effective
compared with either generic or branded clopidogrel in
combination with ASA for treating ACS patients from a
healthcare payer perspective. Our model was composed
of a one-year decision tree and a Markov model to cap-
ture short- and long-term outcomes. We found that the
price of clopidogrel had the greatest impact on ICER.
Compared with generic clopidogrel (0.94 THB per day),
ticagrelor had a cost per QALY gained of 292,504 THB
which was greater than the threshold of 160,000 THB/
QALY. However, when branded clopidogrel was used as
the comparator, ticagrelor treatment was cost-effective
within the predefined threshold for Thailand.
This study is predicated on the assumption that gen-
eric clopidogrel is equally as efficacious and safe as the
branded counterpart. However, Gomez et al. reported
that most clopidogrel copies are not of equivalent quality
[24]. A high number of impurities were found in many
copies; over 60% of the generic copies contained more
than four times the amount of hydrolysis product or
R-enantiomer compared with branded clopidogrel. In
addition, 50% of the samples did not comply with the
95–105% limits for content. As a consequence, the re-
sults of ACS treatment with generic clopidogrel might
not be the same as branded clopidogrel, especially in a
very high-risk group, which would affect the conclu-
sions of our analysis.
Several limitations of this study need to be mentioned.
Firstly, the information on short-term resource use for
the treatment of ACS was based on data from the
PLATO trial [7], which was conducted in accordance
with a strict protocol, and may not accurately reflect real
practice in ACS management in Thailand. We recon-
ciled this overestimated cost by using the unit cost item
from Thai data.
Secondly, due to a paucity of data from Thailand, we
estimated the cost of the no-event state in the Markov
model from outpatient visit and investigation costs from
the 1-year cost of MI reported in Anukoolsawat [4], but
excluding inpatient and intervention costs. As a result,
the no-event total cost was higher than the total cost of
2nd year stroke in the Markov model. This limitation
was due to the fact that available published reports on
the cost of MI and stroke were based on data collected
from two different centers, a medical school (for MI) and













-100.0% -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0%
+/- 20% Probability myocardial infraction Markov model [0.01 : 0.05]
+/- 20% HR over standard mortality in post MI state [1.0 : 4.0]
+/- 20% HR over standard mortality in no event state [1.0 : 4.0]
+/- 20% Cost no event within trial ticagrelor [93,923 : 140,885]
+/- 20% Cost no event within trial clopidogrel [96,245 : 144,368]
+/- 10% Daily cost of clopidogrel [79.78 : 0.85]
% increase from base case % decrease from base case 
Figure 2 Tornado diagram for one-way sensitivity analysis of ticagrelor vs. clopidogrel.
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might not be comparable because of different treatment
and resource use patterns at different centers. To ad-
dress this, we tested the impact of stroke cost param-
eters on the model results in the sensitivity analyses.
We varied the cost of stroke during the first year and
from year 2 onwards in the Markov model by 100%
and found that the ICER results were not sensitive to
these two parameters.
A third limitation arises from the structure of the
Markov model, which does not explicitly allow patients
to suffer multiple cardiovascular events in their lifetime.
Furthermore, this study is based on a payer perspective
and limited only to direct medical costs. Direct non-
medical costs such as transportation or indirect costs











0 100000 200000 30
Ticagrelor vs. branded clopidogrel
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= 160,000 THB
Figure 3 Cost-effectiveness acceptability curves.The finding from Anukoolsawat [4] reported that ACS
was associated with a high economic burden for patients
and their families resulting from loss of productivity, and
that the indirect cost of ACS was even higher than the dir-
ect health care costs. Therefore, excluding these types of
costs underestimates the true total cost of ACS to Thai
society.
Conclusions
This health economic analysis supports the cost effect-
iveness of ticagrelor compared with branded clopidogrel
in Thailand. The ICER of ticagrelor compared with bran-
ded clopidogrel is 60,055 THB/QALY. Therefore, ticagre-
lor appears to be an economically valuable treatment for
ACS compared with branded clopidogrel within the Thai
context.0000 400000 500000 600000
Ticagrelor vs. generic clopidogrel
WHO – threshold
3GDP = 523,974 THB
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